MBX Biosciences, Inc. - MBX STOCK NEWS

MBX Biosciences published Phase 1 study results of MBX 2109, their parathyroid hormone peptide prodrug for hypoparathyroidism treatment, in The Journal of Clinical Endocrinology and Metabolism. The multiple ascending dose study involved 40 participants receiving four once-weekly subcutaneous doses. Key findings showed long half-lives (79-95 hours for prodrug, 184-213 hours for active drug), flat exposure profiles, and dose-proportional increases in serum calcium. The treatment was generally well-tolerated with mostly mild adverse events. The company expects to complete Phase 2 Avail™ trial enrollment in Q1 2025 with topline results in Q3 2025.

MBX Biosciences announced the completion of the last subject's last visit in its Phase 1 trial of MBX 1416, a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH) treatment. The randomized, double-blind, placebo-controlled study enrolled 69 participants to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses in healthy adults. The company expects to release topline results in early January 2025. The trial represents a significant milestone in developing a treatment for PBH, a condition currently without approved therapies.

MBX Biosciences reported Q3 2024 financial results, highlighting a successful transition to public trading and advancement of clinical programs. The company raised $251.2 million through an IPO and Series C financing, with $277.1 million in cash expected to fund operations into mid-2027. Key developments include anticipated completion of MBX 1416 Phase 1 trial by late November with topline results in January 2025, and ongoing Phase 2 Avail™ trial of MBX 2109 for hypoparathyroidism expected to complete enrollment in Q1 2025. Q3 financial results showed R&D expenses of $16.7 million and a net loss of $18.1 million.

MBX Biosciences (NASDAQ: MBX), a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, has announced its participation in three major investor conferences in November 2024. The company will attend the Guggenheim Inaugural Healthcare Innovation Conference in Boston (Nov 12), the Stifel 2024 Healthcare Conference in New York (Nov 18), and the Jefferies London Healthcare Conference (Nov 20). Each session will feature either a fireside chat or company presentation format. Live webcasts will be available on the MBX Biosciences investor website, with replays accessible for approximately 90 days after each event.

MBX Biosciences presented the design and rationale of its Phase 2 Avail™ trial for MBX 2109, a potential long-acting parathyroid hormone (PTH) peptide prodrug, at the ASBMR 2024 Annual Meeting. The trial targets adults with hypoparathyroidism (HP) and aims to normalize serum calcium levels, reduce the need for vitamin D and calcium supplements, and improve patient convenience. The Phase 2 trial is a 12-week, double-blind, placebo-controlled study involving 48 participants. It commenced dosing in August 2024, and topline results are expected in Q3 2025. The primary endpoint is the proportion of patients who can discontinue active vitamin D and reduce calcium supplements to ≤600 mg/day while maintaining normal calcium levels. Secondary endpoints include safety, pharmacokinetics, pharmacodynamics, and quality of life. An extension study will follow for participants completing the 12-week treatment.

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company, has successfully closed its upsized initial public offering. The company sold 11,730,000 shares of common stock at $16.00 per share, including the full exercise of the underwriters' option to purchase additional shares. This resulted in aggregate gross proceeds of approximately $187.7 million, before deducting underwriting discounts, commissions, and offering expenses.

The shares began trading on the Nasdaq Global Select Market on September 13, 2024, under the ticker symbol 'MBX'. J.P. Morgan, Jefferies, Stifel, and Guggenheim Securities acted as joint book-running managers for the offering.

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, has priced its initial public offering (IPO) at $16.00 per share. The company is offering 10,200,000 shares, aiming to raise $163.2 million in gross proceeds. MBX has also granted underwriters a 30-day option to purchase an additional 1,530,000 shares. Trading is expected to begin on September 13, 2024, on the Nasdaq Global Select Market under the ticker symbol "MBX". The IPO is set to close on September 16, 2024, subject to customary conditions. J.P. Morgan, Jefferies, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering.